Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

The mGluR theory of fragile X mental retardation

Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580

Absence of expression of the FMR-1 gene in fragile X syndrome

Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476

Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation

Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005596502855 · Cited by 1,223

Correction of Fragile X Syndrome in Mice

Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979

DNA methylation represses FMR-1 transcription in fragile X syndrome

Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680

The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses

Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676

Advances in the Treatment of Fragile X Syndrome

Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521

Pharmacological Rescue of Synaptic Plasticity, Courtship Behavior, and Mushroom Body Defects in a Drosophila Model of Fragile X Syndrome

McBride, S. M. J., Choi, C. H., Wang, Y., Liebelt, D. A., Braunstein, E. M., Ferreiro, D., Sehgal, A., Siwicki, K. K., Dockendorff, T. C., Nguyen, H. T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.038 · Cited by 484

Individual differences in reward responding explain placebo-induced expectations and effects

Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A., & Zubieta, J.-K. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.028 · Cited by 466

Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome

Erickson, C. A., Wink, L. K., Ray, B., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., Patrick, V. B., Lahiri, D. K., & McDougle, C. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3022-z · Cited by 105

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice

Gantois, I., Pop, A. S., de Esch, C. E. F., Buijsen, R. A. M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B. A., D’Hooge, R., & Willemsen, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.059 · Cited by 100

Effect of Insulin Sensitizer Therapy on Amino Acids and Their Metabolites

Irving, B. A., Carter, R. E., Soop, M., Weymiller, A., Syed, H., Karakelides, H., Bhagra, S., Short, K. R., Tatpati, L. L., Barazzoni, R., et al. (2015) · Metabolism · doi:10.1016/j.metabol.2015.01.008 · Cited by 96

New drugs for children and adolescents with cancer: the need for novel development pathways

Vassal, G., Zwaan, C. M., Ashley, D. M., Deley, M. L., Hargrave, D. R., Blanc, P., & Adamson, P. C. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70013-5 · Cited by 101

Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development

Pop, A. S., Gomez‐Mancilla, B., Neri, G., Willemsen, R., & Gasparini, F. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3330-3 · Cited by 101

Fragile X syndrome due to a missense mutation

Myrick, L. K., Nakamoto-Kinoshita, M., Lindor, N. M., Kirmani, S., Cheng, X., & Warren, S. T. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2013.311 · Cited by 109

Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant

Pop, A. S., Levenga, J., de Esch, C. E. F., Buijsen, R. A. M., Nieuwenhuizen, I. M., Li, T., Isaacs, A., Gasparini, F., Oostra, B. A., & Willemsen, R. (2014) · Psychopharmacology · doi:10.1007/s00213-012-2947-y · Cited by 93

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer

Vassal, G., Rousseau, R. F., Blanc, P., Moreno, L., Bode, G., Schwoch, S., Schrappe, M., Skolnik, J. M., Bergman, L., Bradley‐Garelik, M. B., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.029 · Cited by 95

The Alzheimer’s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway

Jendresen, C., Årskog, V., Daws, M. R., & Nilsson, L. N. G. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0835-4 · Cited by 94

Caspase-11, a specific sensor for intracellular lipopolysaccharide recognition, mediates the non-canonical inflammatory pathway of pyroptosis

Huang, X., Feng, Y., Xiong, G., Whyte, S. K., Duan, J., Yang, Y., Wang, K., Yang, S., Geng, Y., Ou, Y., et al. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0292-0 · Cited by 95

High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome

Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115588287 · Cited by 87

Novel Therapeutic Approach for Excitatory/Inhibitory Imbalance in Neurodevelopmental and Neurodegenerative Diseases

Ghatak, S., Talantova, M. V., McKercher, S. R., & Lipton, S. A. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032320-015420 · Cited by 90

Comparison of Binding Characteristics and In Vitro Activities of Three Inhibitors of Vascular Endothelial Growth Factor A

Yang, J., Wang, X., Fuh, G., Yu, L., Wakshull, E., Khosraviani, M., Day, E. S., Demeule, B., Liu, J., Shire, S. J., et al. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500160v · Cited by 87

FMR1 premutation and full mutation molecular mechanisms related to autism

Hagerman, R., Au, J., & Hagerman, P. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9084-5 · Cited by 85

Development and Prospects of Dedicated Tracers for the Molecular Imaging of Bacterial Infections

Bunschoten, A., Welling, M. M., Termaat, M. F., Sathekge, M. M., & van Leeuwen, F. W. B. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4003037 · Cited by 85

Mechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome

Berry‐Kravis, E. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.12.001 · Cited by 86

Human pluripotent stem cell–derived models and drug screening in CNS precision medicine

Silva, M. C., & Haggarty, S. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14012 · Cited by 88

The effects of storage temperature on PBMC gene expression

Yang, J., Diaz, N., Adelsberger, J. W., Zhou, X., Stevens, R. A., Rupert, A. W., Metcalf, J. A., Baseler, M., Barbon, C. M., Imamichi, T., et al. (2016) · BMC Immunology · doi:10.1186/s12865-016-0144-1 · Cited by 83

Epilepsy associated with autism and attention deficit hyperactivity disorder: Is there a genetic link?

Lo‐Castro, A., & Curatolo, P. (2013) · Brain and Development · doi:10.1016/j.braindev.2013.04.013 · Cited by 86

A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome

Ligsay, A., Dijck, A. V., Nguyen, D. V., Lozano, R., Chen, Y., Bickel, E., Hessl, D. R., Schneider, A., Angkustsiri, K., Tassone, F., et al. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9207-8 · Cited by 83

Prospects for Improving Brain Function in Individuals with Down Syndrome

Costa, A. C. S., & Scott-McKean, J. J. (2013) · CNS Drugs · doi:10.1007/s40263-013-0089-3 · Cited by 83

Developing Electronic Health Record Algorithms That Accurately Identify Patients With Systemic Lupus Erythematosus

Barnado, A., Casey, C. G., Carroll, R. J., Wheless, L., Denny, J. C., & Crofford, L. J. (2016) · Arthritis Care & Research · doi:10.1002/acr.22989 · Cited by 80

Pharmacotherapy for mental health problems in people with intellectual disability

Ji, N. Y., & Findling, R. L. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000233 · Cited by 80

Health and Economic Consequences of Fragile X Syndrome for Caregivers

Bailey, D. B., Raspa, M., Bishop, E. E., Mitra, D., Martin, S. A., Wheeler, A., & Sacco, P. (2012) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318272dcbc · Cited by 76

mGlu5negative allosteric modulators: a patent review (2013 - 2016)

Emmitte, K. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280466 · Cited by 77

Drosophila strategies to study psychiatric disorders

van Alphen, B., & van Swinderen, B. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.09.007 · Cited by 77

Allosteric and Biased G Protein-Coupled Receptor Signaling Regulation: Potentials for New Therapeutics

Khoury, E., Clément, S., & Laporte, S. A. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00068 · Cited by 81

Neurobiology of autism gene products: towards pathogenesis and drug targets

Kleijer, K. T. E., Schmeißer, M. J., Krueger‐Burg, D., Boeckers, T. M., Scheiffele, P., Bourgeron, T., Brose, N., & Burbach, J. P. H. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3403-3 · Cited by 80

Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label study

Çaku, A., Pellerin, D., Bouvier, P., Riou, E., & Corbin, F. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36750 · Cited by 77

Dynamics and modulation of metabotropic glutamate receptors

Rondard, P., & Pin, J. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.001 · Cited by 71

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

Jacquemont, S., Pacini, L., Jønch, A. E., Cencelli, G., Rozenberg, I., He, Y., D’Andrea, L., Pedini, G., Eldeeb, M., Willemsen, R., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy099 · Cited by 73

Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder

Thurman, A. J., McDuffie, A., Hagerman, R., & Abbeduto, L. (2014) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2014.01.032 · Cited by 70

Enhancing the value of psychiatric mouse models; differential expression of developmental behavioral and cognitive profiles in four inbred strains of mice

Molenhuis, R. T., de Visser, L., Bruining, H., & Kas, M. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.01.013 · Cited by 71

Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives

Persico, A. M., Arango, C., Buitelaar, J. K., Correll, C. U., Glennon, J. C., Hoekstra, P. J., Moreno, C., Vitiello, B., Vorstman, J. A. S., & Zuddas, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.009 · Cited by 73

The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome

Uzunova, G., Hollander, E., & Shepherd, J. D. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660046 · Cited by 73

The Chorioallantoic Membrane Assay for Biomaterial Testing in Tissue Engineering: A Short-Term In Vivo Preclinical Model

Moreno-Jiménez, I., Kanczler, J. M., Hulsart‐Billström, G., Inglis, S., & Oreffo, R. O. C. (2017) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2017.0186 · Cited by 70

Excess Protein Synthesis in FXS Patient Lymphoblastoid Cells Can Be Rescued with a p110β-Selective Inhibitor

Groß, C., & Bassell, G. J. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00363 · Cited by 70

Expanded carrier screening in reproductive healthcare: perspectives from genetics professionals

Cho, D., McGowan, M. L., Metcalfe, J., & Sharp, R. R. (2013) · Human Reproduction · doi:10.1093/humrep/det091 · Cited by 69

Hydrogen sulfide ameliorates learning memory impairment in APP/PS1 transgenic mice: A novel mechanism mediated by the activation of Nrf2

Liu, Y., Deng, Y., Liu, H., Yin, C., Li, X., & Gong, Q. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.11.002 · Cited by 68

A systematic review of the methodological and practical challenges of undertaking randomised-controlled trials with cognitive disability populations

Mulhall, P., Taggart, L., COATES, V. E., McAloon, T., & Hassiotis, A. (2018) · Social Science & Medicine · doi:10.1016/j.socscimed.2018.01.032 · Cited by 66

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Berry‐Kravis, E., Hagerman, R. J., Budimirovic, D. B., Erickson, C. A., Heussler, H., Tartaglia, N. R., Cohen, J., Tassone, F., Dobbins, T. W., Merikle, E. P., et al. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09466-6 · Cited by 71

Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions

Murray, D., & Stoessl, A. J. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.009 · Cited by 72

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Hagerman, R. J., Lozano, R., & Hare, E. B. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s42919 · Cited by 70

Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

Wolfe, T. J. D., Eggers, S. I., Barker, A., Kates, A., Dill‐McFarland, K. A., Suen, G., & Safdar, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204253 · Cited by 69

Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned

Bianco, F., Salomone, F., Milesi, I., Murgia, X., Bonelli, S., Pasini, E., Dellacà, R. L., Ventura, M. L., & Pillow, J. J. (2021) · Respiratory Research · doi:10.1186/s12931-020-01585-9 · Cited by 65

Nanodiamond mediated delivery of chemotherapeutic drugs

Li, Y., Zhou, X., Wang, D., Yang, B., & Yang, P. (2011) · Journal of Materials Chemistry · doi:10.1039/c1jm10926j · Cited by 65

“It's Not Like Judgment Day”: Public Understanding of and Reactions to Personalized Genomic Risk Information

Gordon, E. S., Griffin, G., Wawak, L., Pang, H., Gollust, S. E., & Bernhardt, B. A. (2011) · Journal of Genetic Counseling · doi:10.1007/s10897-011-9476-4 · Cited by 64

Drosophila models of early onset cognitive disorders and their clinical applications

van der Voet, M., Nijhof, B., Oortveld, M. A. W., & Schenck, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.01.013 · Cited by 68

Larval zebrafish model for studying the effects of valproic acid on neurodevelopment: An approach towards modeling autism

Dwivedi, S., Medishetti, R., Rani, R., Sevilimedu, A., Kulkarni, P., & Yogeeswari, P. (2018) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2018.11.006 · Cited by 66

International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors

Gregory, K. J., & Goudet, C. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.019133 · Cited by 65

Treatment of Neurodevelopmental Disorders in Adulthood

Ċastrén, E., Elgersma, Y., Maffei, L., & Hagerman, R. J. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.3287-12.2012 · Cited by 69

Fragile X syndrome and fragile X-associated tremor ataxia syndrome

Hall, D. A., & Berry‐Kravis, E. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63233-3.00025-7 · Cited by 65

Applications of Topological Data Analysis in Oncology

Bukkuri, A., Andor, N., & Darcy, I. K. (2021) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2021.659037 · Cited by 74

Inhibition of Group I Metabotropic Glutamate Receptors Reverses Autistic-Like Phenotypes Caused by Deficiency of the Translation Repressor eIF4E Binding Protein 2

Aguilar‐Valles, A., Matta‐Camacho, E., Khoutorsky, A., Gkogkas, C. G., Nader, K., Lacaille, J., & Sonenberg, N. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4615-14.2015 · Cited by 62

A novel library screen identifies immunosuppressors that promote osteoblast differentiation

Darcy, A., Meltzer, M., Miller, J., Lee, S. S., Chappell, S., Donck, K. V., & Montano, M. A. (2012) · Bone · doi:10.1016/j.bone.2012.03.001 · Cited by 60

Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities

Lauschke, V. M., Barragán, I., & Ingelman‐Sundberg, M. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-053021 · Cited by 63

G protein-coupled receptor signalling in astrocytes in health and disease: A focus on metabotropic glutamate receptors

Bradley, S. J., & Challiss, R. A. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.04.009 · Cited by 66

APOE and BDNF Val66Met polymorphisms combine to influence episodic memory function in older adults

Ward, D. D., Summers, M. J., Saunders, N. L., Janssen, P., Stuart, K. E., & Vickers, J. C. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.06.022 · Cited by 64

Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome

Wheeler, A., Raspa, M., Bann, C., Bishop, E. E., Hessl, D. R., Sacco, P., & Bailey, D. B. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36232 · Cited by 66

Enhanced expression of ADCY1 underlies aberrant neuronal signalling and behaviour in a syndromic autism model

Sethna, F., Feng, W., Ding, Q., Robison, A. J., Feng, Y., & Wang, H. (2017) · Nature Communications · doi:10.1038/ncomms14359 · Cited by 62

AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization

Vranesic, I., Ofner, S., Flor, P. J., Bilbe, G., Bouhelal, R., Enz, A., Desrayaud, S., McAllister, K., Kuhn, R., & Gasparini, F. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.09.033 · Cited by 59

mGlu5negative allosteric modulators: a patent review (2010 – 2012)

Emmitte, K. A. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.760544 · Cited by 59

Medication Utilization for Targeted Symptoms in Children and Adults With Fragile X Syndrome

Bailey, D. B., Raspa, M., Bishop, E. E., Olmsted, M. G., Mallya, U. G., & Berry‐Kravis, E. (2011) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318236c0e1 · Cited by 59

A review on pharmacophoric designs of antiproliferative agents

Rana, A., Alex, J. M., Chauhan, M., Joshi, G., & Kumar, R. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1196-5 · Cited by 58

Pleiotrophin mediates hematopoietic regeneration via activation of RAS

Himburg, H. A., Yan, X., Doan, P. L., Quarmyne, M., Micewicz, E., McBride, W. H., Chao, N. J. A., Slamon, D. J., & Chute, J. P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76838 · Cited by 58

Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice

Iliff, A. J., Renoux, A. J., Krans, A., Usdin, K., Sutton, M. A., & Todd, P. K. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds525 · Cited by 57

Allosteric Modulation of Metabotropic Glutamate Receptors

Sheffler, D. J., Gregory, K. J., Rook, J. M., & Conn, P. J. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385952-5.00010-5 · Cited by 62

Targeted Reactivation of FMR1 Transcription in Fragile X Syndrome Embryonic Stem Cells

Haenfler, J. M., Skariah, G., Rodriguez, C. M., da Rocha, A. M., Parent, J. M., Smith, G. D., & Todd, P. K. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00282 · Cited by 59

Positron Emission Tomography (PET) Quantification of GABAA Receptors in the Brain of Fragile X Patients

D’Hulst, C., Heulens, I., der Aa, N. V., Goffin, K. E., Koole, M. J. B., Porke, K., de Velde, M. V., Rooms, L., Paesschen, W. V., Esch, H. V., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131486 · Cited by 56

Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models

Haggarty, S. J., Silva, M. C., Cross, A. J., Brandon, N. J., & Perlis, R. H. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.01.011 · Cited by 57

Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome

Winarni, T. I., Schneider, A., Borodyanskara, M., & Hagerman, R. J. (2012) · Case Reports in Genetics · doi:10.1155/2012/280813 · Cited by 54

Self‐injurious behaviour in intellectual disability syndromes: evidence for aberrant pain signalling as a contributing factor

Peebles, K. A., & Price, T. J. (2011) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2011.01484.x · Cited by 57

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

Frantz, M., Pellissier, L. P., Pflimlin, E., Loison, S., Gandía, J., MARSOL, C., Durroux, T., Mouillac, B., Becker, J. A. J., Merrer, J. L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00697 · Cited by 58

Multi-fidelity classification using Gaussian processes: Accelerating the prediction of large-scale computational models

Costabal, F. S., Perdikaris, P. G., Ellen Kuhl, A., & Hurtado, D. E. (2019) · Computer Methods in Applied Mechanics and Engineering · doi:10.1016/j.cma.2019.112602 · Cited by 55

Inferring cell state by quantitative motility analysis reveals a dynamic state system and broken detailed balance

Kimmel, J. C., Chang, A. Y., Brack, A. S., & Marshall, W. F. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005927 · Cited by 54

Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome

Berry‐Kravis, E., Sumis, A. M., Hervey, C., & Mathur, S. (2012) · International Journal of Pediatrics · doi:10.1155/2012/843016 · Cited by 54

Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial vasa vasorum, but not from the arterial lumen: a hypothesis

Subbotin, V. M. (2012) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-9-11 · Cited by 54

Genetic influence on the working memory circuitry: Behavior, structure, function and extensions to illness

Karlsgodt, K. H., Bachman, P., Winkler, A. M., Bearden, C. E., & Glahn, D. C. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.08.016 · Cited by 58

Immobilization of Growth Factors for Cell Therapy Manufacturing

Enriquez-Ochoa, D., Robles-Ovalle, P., Mayolo‐Deloisa, K., & Brunck, M. E. G. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00620 · Cited by 58

Pathways to Drug Development for Autism Spectrum Disorders

Hampson, D. R., Gholizadeh, S., & Pacey, L. K. K. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.245 · Cited by 56

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure

Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53

Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications

Shen, Y., & Niswender, C. M. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.022 · Cited by 63

Development of an Expressive Language Sampling Procedure in Fragile X Syndrome

Berry‐Kravis, E., Doll, E. R., Sterling, A. M., Kover, S. T., Schroeder, S. M., Mathur, S., & Abbeduto, L. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31828742fc · Cited by 55

Target Selectivity of FimH Antagonists

Scharenberg, M., Schwardt, O., Rabbani, S., & Ernst, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3010338 · Cited by 53

Topological methods reveal high and low functioning neuro‐phenotypes within fragile X syndrome

Romano, D., Nicolau, M., Quintin, E., Mazaika, P. K., Lightbody, A. A., Hazlett, H. C., Piven, J., Carlsson, G., & Reiss, A. L. (2014) · Human Brain Mapping · doi:10.1002/hbm.22521 · Cited by 52

Novel osteoinductive photo-cross-linkable chitosan-lactide-fibrinogen hydrogels enhance bone regeneration in critical size segmental bone defects

Kim, S., Bedigrew, K. M., Guda, T., Maloney, W. J., Park, S.-W., Wenke, J. C., & Yang, Y. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.08.028 · Cited by 53

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope

Hernández-López, A., Téllez‐González, M. A., Mondragón‐Terán, P., & Meneses‐Acosta, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720692 · Cited by 52

Psychophysiological Responses to Emotional Stimuli in Children and Adolescents with Autism and Fragile X Syndrome

Cohen, S., Masyn, K. E., Mastergeorge, A. M., & Hessl, D. R. (2013) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2013.843462 · Cited by 53

Vitamin D in a Northern Canadian First Nation Population: Dietary Intake, Serum Concentrations and Functional Gene Polymorphisms

Larcombe, L., Mookherjee, N., Slater, J. J., Slivinski, C., Singer, M., Whaley, C., Denechezhe, L., Matyas, S., Turner-Brannen, E., Nickerson, P. W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049872 · Cited by 51

Clinical trials for neurodevelopmental disorders: At a therapeutic frontier

Jeste, S. S., & Geschwind, D. H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9874 · Cited by 51

Routes for Drug Translocation Across the Blood-Brain Barrier: Exploiting Peptides as Delivery Vectors

Kristensen, M., & Brodin, B. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.080 · Cited by 52

Cell-free DNA beyond a biomarker for rejection: Biological trigger of tissue injury and potential therapeutics

Tsuji, N., & Agbor-Enoh, S. T. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.03.007 · Cited by 50

DNA Methylation, Mechanisms of FMR1 Inactivation and Therapeutic Perspectives for Fragile X Syndrome

Nobile, V., Pucci, C., Chiurazzi, P., Neri, G., & Tabolacci, E. (2021) · Biomolecules · doi:10.3390/biom11020296 · Cited by 48

Fragile X syndrome: From targets to treatments

Wijetunge, L. S., Chattarji, S., Wyllie, D. J. A., & Kind, P. C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.028 · Cited by 54

Extended Blood Group Molecular Typing and Next-Generation Sequencing

Liu, Z., Liu, M., Mercado, T., Illoh, O., & Davey, R. (2014) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2014.08.003 · Cited by 49

Identification of novel GLUT inhibitors

Siebeneicher, H., Bauser, M., Buchmann, B., Heisler, I., Müller, T. H., Neuhaus, R., Rehwinkel, H., Telser, J., & Zorn, L. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.050 · Cited by 49

Metabotropic Glutamate Receptors in Central Nervous System Diseases

Golubeva, A. V., Moloney, R. D., O’Connor, R. M., Dinan, T. G., & Cryan, J. F. (2016) · Current Drug Targets · doi:10.2174/1389450116666150316224011 · Cited by 51

Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer’s Disease

Pereira, J. B., van Westen, D., Stomrud, E., Strandberg, T. O., Volpe, G., Westman, E., & Hansson, O. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx236 · Cited by 48

Predicting drug‐induced arrhythmias by multiscale modeling

Costabal, F. S., Jiang, Y. D., & Ellen Kuhl, A. (2018) · International Journal for Numerical Methods in Biomedical Engineering · doi:10.1002/cnm.2964 · Cited by 46

Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish

McCammon, J. M., & Sive, H. L. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.019620 · Cited by 51

Epigenetic modification of the FMR1 gene in fragile X patients leads to a differential response to the mGluR5 antagonist AFQ056

Jacquemont, S., Curie, A., Portes, V. D., Torrioli, M. G., Berry‐Kravis, E., Hageman, R., Ramos, F. J., Cornish, K. M., He, Y., & neri, G. (2011) · Cited by 2

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Tabolacci, E., Pirozzi, F., Gomez‐Mancilla, B., Gasparini, F., & Neri, G. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-13 · Cited by 15

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome

Doering, L. C., Sourial, M. M., & Cheng, C. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s27044 · Cited by 8

mGlu5 as a potential therapeutic target for the treatment of fragile X syndrome

Robertson, L. (2013) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzt001 · Cited by 1

Fragile X syndrome therapy: to respond or not to respond may be a matter of methylation

Pouladi, M. A. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01663.x · Cited by 1